EC
CRSP icon

EcoR1 Capital’s CRISPR Therapeutics CRSP Stock Holding History

EcoR1 Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.1M Hold
1,389,276
– – 2.8% 9
2025
Q4 		$72.9M Hold
1,389,276
– – 3.31% 6
2025
Q3 		$90M Hold
1,389,276
– – 4.32% 6
2025
Q2 		$67.6M Hold
1,389,276
– – 4% 7
2025
Q1 		$47.3M Hold
1,389,276
– – 2.8% 9
2024
Q4 		$54.7M Hold
1,389,276
– – 2.07% 14
2024
Q3 		$65.3M Hold
1,389,276
– – 2.23% 12
2024
Q2 		$75M Hold
1,389,276
– – 2.3% 14
2024
Q1 		$94.7M Buy
+1,389,276
New +$99.5M 2.4% 15
2022
Q1 		– Sell
-1,077,483
Closed -$81.7M – 89
2021
Q4 		$81.7M Buy
+1,077,483
New +$94.1M 2.6% 11
2020
Q2 		– Sell
-30,510
Closed -$1.29M – 52
2020
Q1 		$1.29M Buy
+30,510
New +$1.58M 0.14% 42
2019
Q3 		– Sell
-1,610,250
Closed -$75.8M – 39
2019
Q2 		$75.8M Sell
1,610,250
-268,027
-14% -$10.7M 7.66% 4
2019
Q1 		$67.1M Buy
1,878,277
+1,669,427
+799% +$57.7M 6.18% 4
2018
Q4 		$5.97M Sell
208,850
-291,150
-58% -$10.1M 0.6% 39
2018
Q3 		$22.2M Buy
+500,000
New +$26.2M 2% 15

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital's CRSP Position: Q1 2026 in Review

EcoR1 Capital held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 1,389,276 shares worth $66.1M. The position accounts for 2.8% of the portfolio, ranked #9.

EcoR1 Capital first reported a position in CRSP in Q3 2018 and has held it in 15 quarters since. The position peaked at $94.7M in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • EcoR1 Capital held 1,389,276 shares of CRISPR Therapeutics worth $66.1M as of Q1 2026.
  • EcoR1 Capital left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up 2.8% of EcoR1 Capital's portfolio in Q1 2026, its #9 holding.
  • EcoR1 Capital first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 15 quarters since.
  • EcoR1 Capital's CRISPR Therapeutics position peaked at $94.7M in Q1 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on EcoR1 Capital's 13F filing for Q1 2026, filed 15 May 2026.